Kornimate/medical-research-clean huggingface dataset:
virtual reality for mindfulness and anxiety reduction in fertility procedures

Conditions: Virtual Reality; Patient Experience

Summary: this study aims to evaluate the effectiveness of a virtual reality (vr)-based mindfulness and meditation intervention in reducing anxiety among patients undergoing fertility-related surgical procedures. anxiety is a common challenge in fertility treatments, often leading to emotional distress and increased pain perception. by incorporating a non-invasive vr intervention, the investigators seek to improve patient experience, minimize preoperative anxiety, and potentially reduce postoperative discomfort and recovery times. this randomized controlled trial (rct) will compare standard care with a vr intervention in a clinical setting, measuring key outcomes such as anxiety levels, pain perception, recovery duration, and overall patient satisfaction. the findings may contribute to more patient centered fertility care, offering an innovative, scalable, and cost-effective approach to anxiety management in reproductive medicine.

this study examines the effectiveness of a virtual reality (vr) mindfulness intervention in reducing anxiety for patients undergoing fertility surgeries. the trial will compare vr with standard care, measuring outcomes like anxiety, pain, recovery time, and patient satisfaction. the results could provide a cost-effective, patient-centered approach to managing anxiety in fertility treatments.

Eligibility criteria:
inclusion criteria: * patients aged 18-50. * scheduled for fertility-related surgical procedures. * able to provide informed consent. exclusion criteria: * history of motion sickness or vr-related discomfort. * cognitive or psychological conditions affecting participation. * procedures requiring emergency intervention.

Keywords: anxiety stress pain perception recovery duration virtual reality
the impact of body weight on clinical and immunological outcomes in relapse-remitting multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: our study aimed to investigate the effect of interferon beta 1a on the clinical and immunological parameters in egyptian relapse-remitting multiple sclerosis patients

until recently, relapsing-remitting multiple sclerosis (rrms) was considered a homogeneous form of multiple sclerosis (ms). variability both in the immunopathology of active demyelinating lesions in ms and in response to immunomodulatory treatments has demonstrated that rrms is a heterogeneous form of ms. an overwhelming number of trials have supported the use of interferon-β (ifn-β) as a first-line immunomodulatory treatment in rrms. approximately 30% of ifn-β treated rrms patients are non-responders (nr) to treatment. despite vast clinical experience in the use of ifn-β, its mechanisms of action have not been fully clarified. interleukin-17 (il-17) is a proinflammatory cytokine that is secreted by a lineage of t cells named th17 cells. the th17 chemokine pathways are essential for the development of central nervous system (cns) autoimmune diseases such as ms. a high il-17 concentration in the serum. of people with rrms is associated with nonresponse to ifn-β therapy. some animal and human studies have shown that ifn-β inhibits the activity of th17 cells.

Eligibility criteria:
inclusion criteria: * age between 18 and 50 years at time of signing informed consent form. * relapsing- remitting multiple sclerosis as per the mcdonald 2017 criteria, including an mri brain satisfying the 2017 radiological criteria. * kurtzke edss step 0.0 - 6.0. * at the time of screening, being treated with a stable dose of interferon beta 1a for at least 6 months. exclusion criteria: * they had been treated in the last 30 days with methylprednisolone * they had changed their ifn-β preparation within the last 18 months * they had other chronic diseases associated with ms * they had been previously treated with immunosuppressive agents

Keywords: multiple sclerosis, ifb 1a
registry of patients with aqp4+ nmosd treated with alexion c5 inhibitor therapies

Conditions: Neuromyelitis Optica Spectrum Disorder; NMOSD; AQP4+ NMOSD

Summary: long-term, multicenter, multinational, observational, registry of patients with aqp4+ nmosd that is designed to collect data on clinical outcomes and safety in patients prescribed alexion c5 inhibitor therapies (c5it). the registry will also collect data on patient reported outcomes (pros), quality of life (qol), and targeted aqp4+ nmosd therapies used to provide evidence on the real-world impact of alxn-c5it on patients with aqp4+ nmosd.

at the time of enrollment in the registry, participant records will be queried for retrospective information about the participant's medical history and aqp4+ nmosd treatment history for the time period beginning 1 year prior to alxn-c5it initiation through registry enrollment. the duration of data collection for the registry will be approximately 5 years from the day the last participant is enrolled.

Eligibility criteria:
inclusion criteria: * participant is ≥ 18 years of age at the time of enrollment in the registry. * participant must have a confirmed diagnosis of aqp4+ nmosd. * at the time of enrollment in the registry, participants must be receiving treatment with alxn-c5it for the purpose of chronic relapse prevention in a manner consistent with the local label. specifically, they should have received at least 1 dose of eculizumab within 4 weeks prior to enrollment or at least 1 dose of ravulizumab within 12 weeks prior to enrollment. * participants must have both the following historical data available to be enrolled in the registry: alxn-c5it dosing information since initiation and number and types of relapses from 1 year prior to alxn-c5it initiation through registry enrollment. exclusion criteria: * participants currently enrolled in an interventional clinical study for the treatment of aqp4+ nmosd in which the intervention is a drug.

Keywords: neuromyelitis optica spectrum disorder nmosd c5 inhibitor therapies aqp4+ nmosd patient registry alexion c5it soliris
study of mk0928 in healthy adult volunteers in a model of insomnia (0928-006)(completed)

Conditions: Insomnia

Summary: a study to evaluate the safety and effectiveness of study of mk0928 in healthy adult volunteers in a model of insomnia for insomnia (a sleep disorder).


Eligibility criteria:
inclusion criteria: * healthy adults who are between the ages of 18 and 64 exclusion criteria: * adults who are diagnosed with insomnia
evaluation of hemostasis time on partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis

Conditions: Irreversible Pulpitis; Partial Pulpotomy

Summary: the aim of this prospective study is to investigate the influence of time taken to achieve hemostasis on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis. objective:- 1. to evaluate clinical and radiographic success of time taken to achieve hemostasis on outcome of partial pulpotomy in mature permanent teeth with clinical signs indicative of irreversible pulpitis. 2. to evaluate ohrqol and pain incidence \& severity after partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis. participants will of age group 18 to 45 years will be included and divided into two groups based on hemostasis time: i(intervention) - 6minutes c (comparison) - 7-12 minutes

title:- evaluation of hemostasis time on partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis. p (population) - mature permanent molars with clinical signs of irreversible pulpitis. i (intervention) - 6minutes c (comparison) - 7-12 minutes o (outcome) - assessment of clinical and radiographic success at 12 months of follow up . assessment of ohrqol at baseline, post-operatively every 24 hours for 1 week \& incidence and severity of pain at baseline and post-operatively every 24 hours till 1 week. time taken to achieve hemostasis has been suggested as a reliable surrogate measure to determine the depth of inflammation in the pulp. in absence of any other intraoperative indicator, it serves as a useful guide to the extent of pulp tissue removal required during pulpotomy. this trial will help formulate evidence based guideline regarding time for hemostasis advisable to achieve optimum success during pulpotomy in teeth with signs indicative of irreversible pulpitis.

Eligibility criteria:
inclusion criteria: * mature permanent mandibular molars with carious pulp exposures and signs suggestive of irreversible pulpitis. * vital pulp with demonstrable bleeding upon entry. * the tooth is restorable. * tooth with mobility and probing depth within normal limits. * soft tissues around the tooth are normal with no swelling or sinus tract. * no evidence of chronic apical periodontitis (pai 1,2) exclusion criteria: * patients who report history of antibiotic intake in past 1 month or analgesic intake in past 3 days. * pregnant women. * absence of opposing teeth * 3rd molars * medically compromised patients . * tenderness on percussion positive * pathologic mobility

Keywords: partial pulpotomy hemostatsis time
boarding ring glasses versus placebo glasses or not glasses in the treatment of vestibular neuritis

Conditions: Vestibular Neuritis

Summary: vestibular neuritis is a brutal and continuous dizzying syndrome of peripheral (vestibular) origin without cochlear or other associated involvement. specifically, vestibular neuritis is inflammation of the nerve that innervates the vestibular canals (the inner ear). it is characterized by the sudden onset of intense and prolonged vertigo accompanied by postural imbalance, nausea and vomiting, without hearing impairment or other neurological symptoms. vestibular neuritis is the second cause of peripheral vertigo after benign paroxysmal positional vertigo. it represents approximately 7% of patients consulting for vertigo. the purpose of this study is to evaluate if wearing boarding ring glasses can be accelerated vestibular compensation.


Eligibility criteria:
inclusion criteria: * adult patients, * patient with vestibular neuritis defined by appearance of continuous rotating vertigo with nausea * patient with spontaneous horizonto-rotating nystagmus beating towards the healthy ear * patient with a postural deviation towards the affected ear; * vestibular hyporeflexia measured at the caloric tests greater than 25% * patient who has given free, enlighten and written consent exclusion criteria: * patient with a history of vertigo of vestibular origin or with vertigo developing for more than 4 days * patient with associated hearing loss or tinnitus * patient with an motor ocular abnormality of central origin * patient refusal or inability to consent

Keywords: vestibular hyporeflexia rotational vertigo horizontal-rotational nystagmus
the changes of plasmacytoid dendritic cells frequency and function during antiviral therapy

Conditions: Chronic Hepatitis B Infection

Summary: pegylated interferon(ifn) α-2a(peg-ifn-α) not only inhibit viral replication, but also play an important role in immune regulation, while entecavir(etv) drugs only inhibit viral replication. in hepatitis b infection, plasmacytoid dendritic cells（pdcs） are the main effector cells in early antiviral innate immune response. this study was aimed at investigating the changes of pdcs frequency and function, and the expression of costimulatory molecules cd86(cluster of differentiation antigen 86) during peg-ifn-αand entecavir(etv) therapy.meanwhile, investigators want to verify whether peg-ifn-α suppressed the virus and the reduction of virus led to the recovery of pdcs function, or peg-ifn-α enhanced pdcs function which gave rise to the decline of the virus.

pegylated interferon α-2a(peg-ifn-α)and entecavir(etv) drugs can inhibit viral replication , but peg-ifn-α also play an important role in immune regulation . in hepatitis b infection, plasmacytoid dendritic cells (pdcs) are the main effector cells in early antiviral innate immune response.peg-ifn-α recommended as the first-line treatment has a higher chance to achieve hbeag seroconversion and even hbsag disappearance than entecavir(etv) drugs, which may be related to the functional activation of pdcs in the case of hepatitis and the function enhancement of pdcs during peg-ifn-α therapy. this study was aimed at investigating the changes of pdcs frequency and function, and the expression of costimulatory molecules cd86 during peg-ifn-αandentecavir(etv) therapy.meanwhile,investigators want to explore whether the decline of hbsag and hbeag resulted in recovery of cd86+pdc function, or recovery of cd86 + pdc function led to the decrease of hbsag and hbeag. several studies demonstrated that hbsag and hbeag could damage pdc function, and the loss of hbsag and hbeag led to recovery of cd86+pdc function.

Eligibility criteria:
inclusion criteria: * hbsag and hbeag positive for more than 6 months, hbvdna detectable with alt(alanine aminotransferase) level abnormal lasted for three months and at least time190 iu/l or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled. exclusion criteria: * active consumption of alcohol and/or drugs * co-infection with human immunodeficiency virus, hepatitis c virus, or hepatitis d virus * history of autoimmune hepatitis * psychiatric disease * evidence of neoplastic diseases of the liver

Keywords: chronic hepatitis b hepatitis b virus pegylated interferon α-2a entecavir plasmacytoid dendritic cells
a study to evaluate the performance of two designs of soft toric lenses

Conditions: Myopia

Summary: the objective of the study is to evaluate the product performance of the bausch + lomb toric investigational contact lenses compared to the currently marketed purevision toric contact lenses.


Eligibility criteria:
inclusion criteria: * subjects must have clear central corneas and be free of any anterior segment disorders. * subjects must be adapted lens wearers, wear a lens in each eye and each lens must be of the same manufacture and brand. * subjects must be myopic and require lens correction * subjects must be habitual wearers of toric soft contact lenses. exclusion criteria: * subjects with any systemic disease currently affecting ocular health or which in the investigator's opinion may have an effect on ocular health during the course of the study. * subjects using any systemic or topical medications that will, in the investigator's opinion, affect ocular physiology or lens performance. * subjects with an active ocular disease or who are using any ocular medication. * subjects with any grade 2 or greater finding during the slit lamp examination. subjects with corneal infiltrates, of any grade, are not eligible. * subjects with any "present" finding during the slit lamp examination that, in the investigator's judgment, interferes with contact lens wear. * subjects who are allergic to any component in the study care products.
safety and efficacy of exercise in type-b aortic dissection

Conditions: Type B Aortic Dissection

Summary: this is a pilot study. the goal of this clinical trial is to evaluate the safety and efficacy of exercise-based cardiac rehabilitation in patients with type-b aortic dissection or intramural hematoma or penetrating ulcer and received endovascular repair. the main questions it aims to answer are: • is exercise-based cardiac rehabilitation safe among these patients? participants will be randomly assigned to receive usual care plus exercise-based cardiac rehabilitation (guided exercise for 3 months in rehabilitation center) or usual care.


Eligibility criteria:
inclusion criteria: * patients with a previous diagnosis of type b aortic dissection or intramural hematoma or penetrating ulcer, who underwent endovascular aortic repair (evar) or evar + supra-aortic shunt surgery for more than 1 month, and no related complications (such as endoleak, stent thrombosis, dissection progression, etc.) were found in the postoperative aortic cta; * able to independently carry out basic daily life activities, participants must be able to complete the baseline assessment and start the designated treatment; * patients voluntarily participate in this study, sign the written informed consent, and are willing to cooperate with the follow-up; exclusion criteria: * acute myocardial infarction occurred 1 month ago; * combined with severe aortic stenosis or regurgitation; * combined with ascending aortic aneurysm or dissection; * acute heart failure occurred 2 weeks ago; * combined with severe hypertrophic obstructive cardiomyopathy; * chronic renal failure stage 5, which is defined as glomerular filtration rate \<15ml/(min·1.73m2) or dialysis; * during the screening examination, the patient's alanine aminotransferase or aspartate aminotransferase is greater than or equal to 5 times the upper limit of the normal value specified by our center; * patients with any medical history that may affect compliance with the program; * patients with severe language, mental or physical disabilities who are unable to participate in the program; * pregnant or lactating women, or those with fertility who are unwilling/unable to take effective contraceptive measures; * patients participating in other interventional clinical trials; * patients with long-term high-intensity exercise habits; * patients who are judged by the researchers to be unsuitable for participation in this study;
study of let-7a and mirna-124 in cases of non-hodgkin's lymphoma and acute leukemia

Conditions: Non Hodgkin Lymphoma and Acute Leukemia

Summary: mirnas are noncoding rnas (ncrnas) that drive post-transcriptional negative regulation of gene expression by promoting the degradation or translational blockade of their target mrnas. mirnas are 21-24-nucleotide-long rna molecules that are processed from longer rna precursors (pri-mirnas) , and either the 5' or the 3' strand of the mature mirna duplex is loaded into the argonaute (ago) family of proteins to form a mirna-induced silencing complex (mirisc) when bound to ago proteins, mature mirnas destabilize or inhibit the translation of partially complementary target mrnasmirna-124 has been shown to be a tumor suppressor, and a decrease in its expression level is typical of tumors of various localization, but there is no evidence of the role of mirna-124 in the development of nhl . there are a number of studies reflecting the involvement of mirna-124 in hematopoiesis. liu et al. showed that mirna-124 regulates tip110 that is involved in the differentiation of hematopoietic stem cellsthe let-7 family has been shown to influence the pathogenesis of a variety of hematological malignancies through the changing expression of a number of oncogenic pathways, particularly those related with myc and that might affect hematopoietic carcinogenesis through the modulation of inflammatory pathways


Eligibility criteria:
inclusion criteria: * approval to sign an informed written consent, * patient with nhl and acute leukemia . exclusion criteria: * refusal to sign an informed written consent, * patient on chemotherapy
effects of pain neuroscience education in fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia is one of the main causes of chronic musculoskeletal widespread pain. this condition presents a global prevalence of 2.7%, and it is more prevalent in women (with a female to male ratio of 3:1) over 50 years of age with low education level and low socioeconomic status, living in rural areas. high direct medical costs and significant indirect costs of this condition can't be ignored.

study design and setting: the design of the present study will be a randomized controlled trial with 2 follow-ups (one week and one month after intervention) that will be performed between may 2017 and june 2017 in one private clinic in malaga, spain. the outcomes will be assessed at baseline (t1), one week after intervention (t2), and one moth after intervention (t3). written informed consent will be acquired for all participants prior to their participation. the study will be implemented and reported in line with the consort statement.

Eligibility criteria:
inclusion criteria: * age between 18-70 years. * willing and able to participate * diagnosis of fibromyalgia exclusion criteria: * systemic diseases * pain and function due to other rheumatic disorders such as: osteoarthritis, rheumatoid arthritis, ankylosing spondylitis.

Keywords: chronic pain fibromyalgia pain neuroscience education exercise
clinical impact of donor milk pasteurized by htst treatment in preterm infants

Conditions: Late-Onset Neonatal Sepsis

Summary: randomized double-blind clinical trial to compare the incidence of microbiological proven late onset sepsis in extremely preterm infants (\<1000 grams) that are supplemented with donor milk pasteurized by high temperature short time (htst) method versus the holder method.

donor milk pasteurized by an innovative high temperature short time (htst) system (patented by researchers) retains more immune and trophic compounds than pasteurized milk by traditional holder method. these compounds are related to the protection conferred by breast milk against nosocomial sepsis and necrotizing enterocolitis in preterm infants, so it would be of interest to study if there is a clinical benefit in these patients when health professionals are supplementing with donor milk pasteurized by both methods. the purpose of this study is to compare the incidence of microbiological proven late onset sepsis in newborns under 1000 grams that in the first 28 days of life need to be supplemented with donor milk pasteurized by htst method versus the holder method. this is a randomized double-blind clinical trial with parallel assignment. a total of 305 premature babies with a birth weight of less than 1000 grams will be recruited, admitted to the neonatology services of the hospital 12 de octubre and the hospital de la paz and meet the inclusion criteria. half of the patients will be supplemented exclusively with donor milk pasteurized by the htst system and the other half with pasteurized milk by the holder method. linear generalized models will be used for longitudinal data analysis.

Eligibility criteria:
inclusion criteria (all criteria are necessary) : * infants weighing 1000 grams or less at birth * infants born or transferred before the third day of life to the participating centers * start enteral feeding in the first week of life * receive any amount of donor milk in the first 28 days of life * informed consent signed by parents or legal guardians exclusion criteria: * language barrier * infants with chromosomopathies * infants with major congenital malformations * infants with severe asphyxiation (cord ph or first arterial ph \<7) * infants included in another clinical trial that modifies nutritional management * infants who previously fed with formula post-randomization exclusion criteria: - randomized infant who do not fulfill inclusion criteria

Keywords: neonatal sepsis extremely low birth weight infant donor milk htst pasteurization holder pasteurization